Augere Medical Gains $2.1M in Its “First Close” Funding Round

Augere Medical has secured $2.1 million in a new funding round for its expanded capabilities. This comes after the MDR CE mark for Augere’s Class IIb PolypAID system. 

David Borge Larsen, Augere’s interim CEO, commented, “Securing this first close financing enables the Augere team to focus on the real task at hand: bringing the PolypAID system to endoscopists and the patients being screened for colon cancer. We thank our investors for the continued support and are looking forward to expanding our customer base.”

The PolypAID system is AI-driven and designed to help clinicians and healthcare providers augment the screening of colorectal cancer. The proceeds raised will be used to strengthen the European sales and marketing efforts as well as hire highly skilled AI development engineers. 

Also, Augere has started regulatory activities towards larger overseas markets and expects to achieve important milestones in these geographies over the next months.